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Combined pulmonary fibrosis and emphysema (CPFE) 
is a clinical syndrome that is characterized by the fol-
lowing findings: a history of smoking; the presence of 
dyspnea, pulmonary hypertension, and hypoxemia; rela-
tively normal spirometry and lung volumes in the context 
of severely impaired gas exchange; radiographically 
confirmed upper- lobe emphysema; lower- lobe fibrosis; 
and poor survival [1–5]. Since Cottin et al. reported 
their comprehensive study of patients with CPFE in 2005, 
CPFE has gradually gained the attention of researchers, 
and is now recognized throughout the world [2, 4]. As 
almost all patients with CPFE are smokers [2, 4], CPFE 
has been recognized as an important risk factor for 
developing lung cancer [4, 6–10]. In addition, lung 
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Abstract
Combined pulmonary fibrosis and emphysema (CPFE) is an important risk 
factor for lung cancer (LC), because most patients with CPFE are smokers. 
However, the histological characteristics of LC in patients with CPFE (LC- CPFE) 
remain unclear. We conducted this study to explore the clinicopathological 
characteristics of LC- CPFE. We retrospectively reviewed data from 985 patients 
who underwent resection for primary LC, and compared the clinicopathological 
characteristics of patients with LC- CPFE and non- CPFE LC. We identified 72 
cases of LC- CPFE, which were significantly associated with squamous cell car-
cinoma (SqCC) histology (n = 46, P < 0.001) and higher tumor grade (n = 44, 
P < 0.001), compared to non- CPFE LC. Most LC- CPFE lesions were contiguous 
with fibrotic areas around the tumor (n = 59, 81.9%), and this association was 
independent of tumor location. Furthermore, dysplastic epithelium was identi-
fied in the fibrotic area for 31 (52.5%) LC- CPFE lesions. Moreover, compared 
to patients with pulmonary fibrosis alone in the non- CPFE group (n = 31), 
patients with CPFE were predominantly male (P = 0.008) and smokers 
(P < 0.001), with LC- CPFE predominantly exhibiting SqCC histology (P = 0.010) 
and being contiguous with the tumor- associated fibrotic areas (P < 0.001). 
Multivariate analysis revealed that CPFE was an independent predictor of overall 
survival (hazard ratio: 1.734; 95% confidence interval: 1.060–2.791; P = 0.028). 
Our results indicate that LC- CPFE has a distinct histological phenotype, can 
arise from the dysplastic epithelium in the fibrotic area around the tumor, and 
is associated with poor survival outcomes.
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cancers in patients with CPFE exhibit a high rate of 
squamous cell carcinoma histology, advanced pathological 
staging, and relatively short survival [7, 9–14]. Therefore, 
it is important to clarify the clinicopathological features 
of lung cancer in patients with CPFE, in order to under-
stand the pathogenesis of CPFE- related lung cancer and 
to develop appropriate treatments. However, the associa-
tion of lung cancer histology with the background his-
tological changes in patients with CPFE remains unclear. 
Therefore, we conducted this retrospective study to 
evaluate the histological characteristics of lung cancer 
in patients with CPFE, using their resected lung 
specimens.
Materials and Methods
We retrospectively evaluated cases of lung resection for 
pulmonary masses, which were treated at Shinshu 
University Hospital between December 1995 and December 
2013, using the hospital’s Thoracic Surgery and Pathology 
database. We used the patients’ electronic medical records 
to retrieve their clinical data, which included age, sex, 
smoking status, tumor location (including laterality and 
lobe), history of connective tissue disease and drug treat-
ment, and follow- up data. Our research protocol was 
reviewed and approved by our institutional ethics review 
committee.
To evaluate the clinicopathological significance of 
lung cancer in patients with CPFE (LC- CPFE) after 
complete tumor resection, we divided patients into LC- 
CPFE and non- CPFE lung cancer groups based on their 
chest high- resolution computed tomography (HRCT) 
findings [7]. Lungs with CPFE were diagnosed using 
Cottin et al.’s criteria [2]: (1) the presence of emphy-
sema on CT scan, which was defined as well- demarcated 
areas of decreased attenuation in comparison with con-
tiguous normal lung and marginated by a very thin 
wall (<1 mm), no wall, and/or multiple bullae (>1 cm) 
with upper zone predominance; and (2) the presence 
of diffuse parenchymal lung disease with significant 
pulmonary fibrosis on CT scan, which was defined as 
reticular opacities with peripheral and basal predomi-
nance, honeycombing, architectural distortion, and/or 
traction bronchiectasis or bronchiolectasis. Focal 
ground- glass opacities and/or areas of alveolar conden-
sation are permissible, although these areas should not 
be prominent (Fig. 1).
We also divided the non- CPFE group into three 
groups to evaluate the prognostic significance of 
 LC- CPFE based on their HRCT images (99.4% of the 
cases were evaluated using HRCT): lung cancer in 
patients with only pulmonary fibrosis (LC- PF), patients 
with only emphysema (LC- Emp), and patients with 
normal lungs (LC- Norm). The radiographical criteria 
for CPFE were used to define the LC- Emp group (ful-
filled criterion 1 only), the LC- PF group (fulfilled cri-
terion two only), and the LC- Norm group (fulfilled 
neither criteria). To account for interobserver variation, 
Figure 1. A representative case of lung cancer in a patient with 
combined pulmonary fibrosis and emphysema. Computed tomography 
reveals (A) bilateral emphysematous changes in the upper lobes and (B) 
a solid mass within the subpleural fibrous- reticular area in the right 
lower lobe. (C) The resected lung specimen reveals a white- tan tumor 
along the fibro- cystic area.
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we omitted the LC- Norm group, and the LC- CPFE, 
LC- PF, and LC- Emp groups were independently deter-
mined by MZ, AY, a radiologist (SK), and two pul-
monologists (MY, HY). All reviewers were blinded to 
the patients’ information, and consensus was used to 
resolve discrepancies in the group assignments. At this 
point, we also excluded patients with pulmonary fibrosis 
that was induced by connective tissue disease and drug 
treatment from the LC- CPFE and LC- PF groups, based 
on their medical records.
To explore the histological characteristics of LC- CPFE, 
all histological slides from that group were reviewed 
under a multiheaded microscope by MZ and two patholo-
gists (AY, SA), who were blinded to the clinical and 
radiological findings. In addition, the histological slides 
from the LC- PF group were reviewed in a similar man-
ner, and their clinicopathological characteristics were 
compared to those of the LC- CPFE group. The histo-
logical subtype was determined according to the 2015 
WHO classification for lung tumors [15], and the TNM 
stage was determined according to the 7th edition of 
the Tumor, Node, and Metastasis classification of the 
International Union Against Cancer [16]. Furthermore, 
we histologically evaluated the area surrounding the tumor 
for various changes, including the presence or absence 
of emphysema (with coverage around the tumor in 5–10% 
increments) and the presence or absence of pulmonary 
fibrosis (with coverage around the tumor in 5–10% 
increments). If a fibrotic area was present around the 
tumor, we also recorded the absence or presence (and 
percent coverage) of metaplastic epithelium, atypical 
metaplastic epithelium, or dysplastic epithelium (both 
squamous and glandular) within the fibrotic area (Fig. 2). 
To distinguish direct extension of the lung cancer into 
the fibrotic area from isolated dysplastic epithelium, we 
defined dysplastic epithelium as foci that were clearly 
separated from the border between the cancerous and 
fibrotic areas and that were accompanied by metaplastic 
epithelium [17].
Statistics
The chi- square test and Fisher’s exact test were used for 
categorical data, as appropriate. Mann–Whitney U tests 
were used for continuous data. The survival rates were 
calculated using the Kaplan–Meier method, and were 
compared using the log- rank test. Multivariate analysis 
was performed using Cox’s proportional hazards model. 
All statistical tests were two- sided and used a 5% level 
of significance. All data analyses and graphing were per-
formed using JMP software (version 8; SAS Institute, Cary, 
NC).
Figure 2. Representative histological features of lung cancer in a patient with combined pulmonary fibrosis and emphysema. (A) A low- power view 
of lung cancer from a patient with combined pulmonary fibrosis and emphysema (hematoxylin and eosin staining). The cancerous area is enclosed by 
the green line, and the fibrotic area around the tumor is enclosed by the orange line. (B) A high- power view of the cancerous area from (A), which 
reveals invasive squamous cell carcinoma. (C) A high- power view of the fibrotic area from (A), which reveals the dysplastic squamous epithelium. (D) 
A high- power view of the surrounding fibrotic area from another case, which reveals the dysplastic glandular epithelium next to the metaplastic 
bronchial epithelium. Bars indicate 5 mm for (A), 250 μm for (B), 100 μm for (C), and 100 μm for (D).
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Results
Comparing the clinicopathological 
characteristics of LC- CPFE and the other 
groups
This study evaluated records from 1647 patients; patients 
without CT images or sufficient clinical and histological 
information, patients with metastatic tumors, and patients 
who had undergone chemo- radiotherapy before surgery were 
excluded. Therefore, we included 985 patients in this study, 
and discovered that this group included 72 patients with 
LC- CPFE, 82 patients with LC- Emp, 31 patients with  LC- PF, 
and 800 patients in the LC- Norm group. The clinicopatho-
logical characteristics of the patients with LC- CPFE and 
non- CPFE lung cancer are summarized in Table 1. Patients 
with LC- CPFE were all smokers, with a mean Brinkman 
index of 1131.7 ± 490.8. Not all patients with LC- CPFE 
underwent pulmonary function testing (available data for 
the CPFE group: FVC [% of predicted], 104.8 ± 19.7%; 
FEV1.0 [% of predicted], 103.2 ± 22.2%; DLCO, 
50.9 ± 16.5%), and there were no patients with CPFE and 
pulmonary hypertension, as patients with pulmonary hyper-
tension are excluded from lung cancer resection at our 
institution. Compared to patients with non- CPFE lung cancer, 
patients with LC- CPFE were predominantly men (n = 67, 
93.0%, P < 0.001) and older (mean age: 70.5 ± 7.3 years, 
P = 0.012). Furthermore, LC- CPFE was associated with a 
larger tumor size (mean size: 29.5 ± 16.0 mm, P < 0.001). 
The numbers of LC- CPFE cases at each pathological stage 
were 20 (27.7%) at stage IA, 22 (30.5%) at stage IB, 14 
(19.4%) at stage IIA, 2 (2.7%) at stage IIB, 10 (13.9%) at 
stage IIIA, and 4 (5.6%) at stage IV; LC- CPFE was associ-
ated with a significantly higher stage, compared to the other 
groups (P < 0.001). The most common histological subtype 
of LC- CPFE was squamous cell carcinoma (n = 46, 63.8%), 
which was followed by adenocarcinoma (n = 19, 26.3%), 
large cell carcinoma (n = 5, 6.7%), small cell carcinoma 
(n = 1, 1.4%), and large cell neuroendocrine carcinoma 
(n = 1, 1.4%). The tumor grade of the LC- CPFE group 
was significantly higher than those in the other groups 
(P < 0.001).
Survival analysis
The curves for overall survival (OS) and disease- free sur-
vival (DFS) in the four groups are shown in Figure 3. 
Table 1. The clinicopathological characteristics of lung cancer in patients with combined pulmonary fibrosis and emphysema (CPFE) and non- CPFE 
conditions.
Parameter Total LC- CPFE LC- non- CPFE P- value
985 72 913
Age (mean) 67.5 ± 9.4 70.5 ± 7.3 67.2 ± 9.5 0.012
Sex Male 540 67 473 <0.001
Female 445 5 440
Smoking his. Current/Former 501 72 429 <0.001
Never 466 0 466
BI (mean) 508 ± 713 1131.7 ± 490.8 458.3 ± 705.3 <0.001
Tumor size (mean, mm) 23.1 ± 14.9 29.5 ± 16.0 22.6 ± 14.7 <0.001
Stage IA 601 20 581 <0.001
IB 194 22 172
IIA 73 14 59
IIB 48 2 46
IIIA 50 10 40
IIIB 9 0 9
IV 10 4 6
His. subtype ADC 779 19 760 <0.001
SqCC 152 46 106
SmCC 6 1 5
LCNEC 18 1 17
LCC 13 5 8
ADSQ 9 0 7
Others 8 0 8
Tumor Grade G1 411 0 411 <0.001
G2 320 28 292
G3- 4 254 44 210
Smoking his., smoking history; BI, Brinkman index; His. Subtype, Histological subtype; ADC, adenocarcinoma; SqCC, squamous cell carcinoma; 
SmCC, small cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; LCC, large cell carcinoma; ADSQ, adenosquamous carcinoma.
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The LC- CPFE group exhibited a significantly poorer DFS, 
compared to the LC- Norm (P < 0.001) and LC- Emp 
(P = 0.001) groups (Fig. 3A). However, patients with 
LC- CPFE and LC- PF had similar DFS (P = 0.664). The 
LC- CPFE group exhibited significantly poorer OS compared 
to the LC- Norm (P < 0.001) and LC- Emp (P = 0.002) 
groups (Fig. 3B). Similarly, the LC- CPFE group exhibited 
a poorer OS compared to the LC- PF group, although the 
difference was not statistically significant (P = 0.060). 
Patients with CPFE adenocarcinoma or squamous cell 
carcinoma exhibited poorer survival outcomes compared 
to patients with non- CPFE adenocarcinoma (OS, 
P < 0.001; DFS, P < 0.001) or non- CPFE squamous cell 
carcinoma (OS, P < 0.001; DFS, P = 0.007).
Table 2 shows the results for the univariate and mul-
tivariate analyses of the various clinicopathological factors 
that we examined. The univariate analysis revealed numer-
ous significant risk factors for poor DFS and OS, and 
patients with CPFE exhibited a higher risk of recurrence 
(hazard ratio [HR]: 4.641; 95% confidence interval [CI]: 
2.824–7.358; P < 0.001) and mortality (HR: 4.993; 95% 
CI: 3.195–7.595; P < 0.001) compared to the patients 
Figure 3. Survival curves. (A) Disease- free survival and (B) overall survival. LC- Norm: lung carcinoma in the normal lung, LC- Emp: lung carcinoma in 
patients with emphysema, LC- PF: lung carcinoma in patients with pulmonary fibrosis, LC- CPFE: lung carcinoma in patients with combined pulmonary 
fibrosis and emphysema.
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without CPFE. The multivariate analysis using the Cox 
proportional hazards model revealed that CPFE was a 
significant and independent predictor of OS (HR: 1.734; 
95% CI: 1.060–2.791; P = 0.028), although it was not an 
independent predictor of DFS (HR: 1.689; 95% CI: 0.974–
2.873; P = 0.061).
Histological characteristics of LC- CPFE
Table 3 shows the associations of the histological change 
in the tumor background with tumor location and his-
tological subtype. Among the 72 cases of LC- CPFE, tumors 
were most common in the right lower lobe (n = 28, 
38.8%), which was followed by the right upper lobe 
(n = 19, 26.3%), the left lower lobe (n = 12, 16.6%), 
the left upper lobe (n = 11, 15.2%), and the right middle 
lobe (n = 2, 2.7%). Approximately half of the LC- CPFEs 
were located in the lower lobes (n = 40, 55.5%). Most 
cases of  LC- CPFE exhibited fibrotic changes around the 
tumor (n = 59, 81.9%), although seven cases of LC- CPFE 
exhibited emphysematous changes around the tumor, and 
six cases of LC- CPFE did not exhibit fibrotic or emphy-
sematous changes around the tumor. We observed meta-
plastic epithelium in the fibrotic area around the tumor 
in all cases (involved area: 5–100%, mean: 45.3%), atypical 
metaplastic epithelium in 33 cases (involved area: 5–30%, 
mean: 8.3%), and dysplastic epithelium in 31 cases 
(involved area: 5–20%, mean: 45.3%). Most cases with 
the squamous cell carcinoma subtype were located con-
tiguous with the fibrotic area (n = 39, 84.7%), and dys-
plastic squamous epithelium in the fibrotic area was 
identified in approximately half of these cases (n = 20, 
51.2%). Most cases with the adenocarcinoma subtype were 
also located contiguous with the fibrotic area (n = 15, 
Table 2. Univariate and multivariate analyses of the clinicopathological parameters.
Parameter
DFS Univariate DFS Multivariate
HR 95%CI P- value HR 95%CI P- value
Age 
(≥70 vs. <70)
1.176 0.768–1.791 0.452 1.063 0.686–1.638 0.781
Sex 
(male vs. female)
2.401 1.523–3.912 <0.001 0.966 0.472–2.052 0.928
Smoking status 
(ever vs. never)
3.099 1.942–5.138 <0.001 1.289 0.565–2.948 0.548
Stage 
(II- IV vs. I)
4.236 2.775–6.440 <0.001 2.486 1.558–3.960 <0.001
Histology 
(non- ADC vs. ADC)
4.904 3.227–7.483 < 0.001 2.602 1.543–4.462 <0.001
Tumor grade 
(G3- 4 vs. G1- 2)
3.304 2.167–5.024 <0.001 1.452 0.900–2.347 0.125
CPFE status 
(CPFE vs. non- CPFE)
4.641 2.824–7.358 <0.001 1.689 0.974–2.873 0.061
Parameter
OS Univariate OS Multivariate
HR 95%CI P- value HR 95% CI P- value
Age 
(≥70 vs. <70)
2.636 1.776–3.945 <0.001 2.277 1.520–3.438 <0.001
Sex 
(male vs. female)
5.087 3.078–8.983 <0.001 1.699 0.784–3.816 0.183
Smoking status 
(ever vs. never)
5.649 3.447–9.835 <0.001 1.917 0.863–4.406 0.111
Stage 
(II- IV vs. I)
2.883 1.929–4.254 <0.001 1.581 1.007–2.459 0.046
Histology 
(non- ADC vs. ADC)
4.671 3.190–6.864 <0.001 1.942 1.244–3.068 0.003
Tumor grade 
(G3- 4 vs. G1- 2)
3.078 2.089–4.513 <0.001 1.336 0.852–2.091 0.205
CPFE status 
(CPFE vs. non- CPFE)
4.993 3.195–7.595 <0.001 1.734 1.060–2.791 0.028
DFS, disease- free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma.
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78.9%), and dysplastic glandular epithelium in the fibrotic 
area was identified in more than half of these cases (n = 10, 
66.6%).
Among the adenocarcinoma cases in the LC- CPFE group 
(n = 19), the most common subclass was solid adenocar-
cinoma (n = 7, 36.8%), which was followed by papillary 
adenocarcinoma (n = 5, 26.3%), acinar adenocarcinoma 
(n = 4, 21.0%), invasive mucinous adenocarcinoma (n = 2, 
10.5%), and lepidic adenocarcinoma (n = 1, 5.2%) (Table 4). 
There were no cases of adenocarcinoma in situ or mini-
mally invasive adenocarcinoma, and no lepidic components 
were observed in the majority of the cases (n = 12, 63.1%).
Comparing LC- CPFE and LC- PF
The clinicopathological characteristics of the patients with 
LC- CPFE and LC- PF group are summarized in Table 4. 
Compared to the LC- PF group, patients with LC- CPFE 
were predominantly men (67 vs. 23, P = 0.008) and 
smokers (72 vs. 20, P < 0.001). Furthermore, LC- CPFE 
was associated with a significantly smaller tumor size 
(mean: 29.5 mm vs. 39.6 mm, P = 0.036). The most 
common histological subtype of LC- CPFE was squamous 
cell carcinoma (n = 46, 63.8%), and the most common 
subtype of LC- PF was adenocarcinoma (n = 17, 54.8%). 
Among the adenocarcinoma cases in the LC- CPFE group, 
the most common subclass was solid adenocarcinoma 
(n = 7, 36.8%), and only one case (3.2%) of solid adeno-
carcinoma was observed in the LC- PF group. Compared 
to the LC- PF lesions, the LC- CPFE lesions were signifi-
cantly more likely to be located along the fibrotic area 
(P < 0.001). The lung cancers along the fibrotic area in 
both groups exhibited dysplastic epithelium in the sur-
rounding fibrotic area, although there was no significant 
difference between the two groups (P = 0.187). Five patients 
in the LC- CPFE group experienced acute exacerbation 
and subsequently died, while three patients died because 
of acute exacerbation in the LC- PF group; this difference 
was not statistically significant (P = 0.634).
Discussion
Since the concept of CPFE was proposed by Cottin et al. 
[2], various researchers have explored the clinicopatho-
logical association between lung cancer and CPFE [7, 9, 
10, 12–14]. In this study, we discovered that patients 
with lung cancer and CPFE were typically smokers, and 
were predominantly male and older (vs. patients with 
non- CPFE lung cancer). Moreover, the lung cancers in 
this study were predominantly squamous cell carcinoma 
with high- grade dysplasia, had progressed to a relatively 
high stage at the time of diagnosis, and exhibited poor 
survival outcomes. These findings are generally compat-
ible with those of the previous studies [7, 9, 10, 13, 14]. 
However, those studies generally evaluated the clinical 
risk and/or incidence of lung cancer in patients with 
CPFE, and no studies have examined the histological 
characteristics of lung cancer in patients with CPFE, or 
the relationship between lung cancer and the histological 
changes around the tumor. This study demonstrated that 
lung cancers in patients with CPFE had developed in 
heterogeneous tumorigenic backgrounds (normal, emphy-
sematous, and fibrotic areas), and that most lung cancers 
were associated with the fibrotic area around the tumor. 
Moreover, dysplastic epithelium in the fibrotic area was 
frequently identified in these cases, which indicates that 
the development of lung cancer in patients with CPFE 
is distinct from the development of lung cancer in patients 
without CPFE.
We found that 55.5% of the lung cancers in patients 
with CPFE were located in the lower lobes, which is 
compatible with the findings of the previous studies 
[9, 13]. However, we also found that most of the lung 
cancers (n = 59, 81.9%) were associated with the fibrotic 
area around the tumor in the patients with CPFE, and 
this relationship was independent of the tumor’s location. 
Furthermore, a majority of our cases (n = 31, 52.5%) 
exhibited dysplastic epithelium in the fibrotic area. Thus, 
we hypothesize that pulmonary fibrosis is strongly 
Table 3. The associations of histological changes in the tumor background with tumor location and histological subtype.
Histological change 
around the tumor
Tumor Location Histological subtype
TotalRUL RML RLL LUL LLL SqCC ADC LCC SmCC LCNEC
Normal 0 0 1 4 1 4 2 0 0 0 6
Emp. 5 1 1 0 0 3 2 2 0 0 7
Fibrotic ()1 14 (4) 1 (0) 26 (14) 7 (5) 11 (8) 39 (20) 15 (10) 3 (1) 1 (0) 1 (0) 59 (31)
Total 19 (4) 2 (0) 28 (14) 11 (5) 12 (8) 46 (20) 19 (10) 5 (1) 1 (0) 1 (0) 72 (31)
Emp., Emphysematous change; Fibrotic., fibrotic change; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left lower lobe; 
LLL, left lower lobe; SqCC, squamous cell carcinoma; ADC, adenocarcinoma; LCC, large cell carcinoma; SmCC, small cell carcinoma; LCNEC, large cell 
neuroendocrine carcinoma.
1The number of () indicates the case with dysplastic epithelium in the fibrotic area.
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associated with lung cancer development in patients with 
CPFE. To the best of our knowledge, this is the first 
report regarding this relationship in patients with CPFE, 
although a few researchers have reported similar findings 
for lung cancer in patients with pulmonary fibrosis. For 
example, Kawasaki et al. analyzed the relationship between 
cancer location and regions of idiopathic pulmonary fibrosis 
(IPF), and reported that 50% of the cancers occurred in 
the fibrotic parenchyma and that 29% of the cancers 
occurred in the marginal area of the fibrosis [18]. 
Furthermore, Khan et al. have reported a striking transi-
tion from metaplastic squamous epithelium (within the 
fibrotic areas) to invasive carcinoma in 50% of the resected 
squamous cell tumors from patients with IPF [17]. Based 
on these findings, it is possible that lung cancer in patients 
with CPFE has a similar developmental process to that 
of lung cancer in patients with IPF, as these two groups 
exhibit increasing epithelial atypia, atypical metaplasia to 
Table 4. The clinicopathological characteristics of lung cancer in patients with combined pulmonary fibrosis and emphysema (LC- CPFE) or pulmonary 
fibrosis (LC- PF).
Parameter
Total LC- CPFE LC- PF
P- value103 72 31
Age 70.4 ± 7.1 70.3 ± 7.3 71.3 ± 7.3 0.751
Sex Male 90 67 23 0.008
Female 13 5 8
Smoking his. Current/Former 92 72 20 <0.001
Never 11 0 11
BI (mean) 978.2 ± 562.0 1131.7 ± 490.8 622.8 ± 97.4 <0.001
Tumor size (mean, mm) 32.5 ± 20.8 29.5 ± 16.0 39.6 ± 28.2 0.036
Stage I 60 42 18 0.380
II 23 16 7
III 15 10 5
IV 5 4 1
Acute Exa. Positive 8 5 3 0.634
Negative 95 67 28
Tumor location RUL 29 19 10 0.999
RML 4 2 2
RLL 37 28 9
LUL 16 11 5
LLL 17 12 5
His. Subtype ADC 36 19 17 0.010
SqCC 55 46 9
SmCC 2 1 1
LCNEC 3 1 2
LCC 7 5 2
Tumor grade G1 6 0 6 0.441
G2 39 28 11
G3- 4 58 44 14
When ADC, subclassification Lepidic 3 1 2 0.639
Acinar 10 4 6
Papillary 11 5 6
Micropapillary 2 0 2
IMA 2 2 0
Solid 8 7 1
When ADC, lepidic comp. Presence 15 7 8 0.534
Absence 21 12 9
Histological change around the tumor Normal 27 6 21 <0.001
Emp. 7 7 0
Fibrotic ()1 69 (33) 59 (31) 10 (3)
Smoking his., smoking history; BI, Brinkman index; Acute Exa., acute exacerbation; His. Subtype, histological subtype; lepidic comp., lepidic compo-
nent; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left lower lobe; LLL, left lower lobe; ADC, adenocarcinoma; SqCC, 
squamous cell carcinoma; SmCC, small cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; LCC, large cell carcinoma; IMA, invasive muci-
nous adenocarcinoma; Emp., Emphysematous change; Fibrotic, fibrotic change.
1The number of () indicates the case with dysplastic epithelium in the fibrotic area.
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carcinoma in situ, and invasive carcinoma in the sur-
rounding fibrotic area. However, this possibility is not 
surprising, as CPFE is not a distinct entity, but rather a 
state of coexistence between pulmonary fibrosis and emphy-
sema [2, 19]. These issues raise the question of whether 
we should clinically differentiate between  LC- CPFE and 
LC- PF. Although most previous studies have highlighted 
a risk of developing lung cancer in patients with CPFE, 
and compared their overall prognosis to patients with 
emphysema or IPF [6, 7, 9, 10], only one study has com-
pared the prognoses of LC- CPFE and LC- PF. In that 
study, Kumagai et al. retrospectively analyzed the effect 
of CPFE on the prognosis of patients with NSCLC after 
complete tumor resection [11], and concluded that CPFE 
was a significant predictor of a poor prognosis for NSCLC. 
In this study, we found that patients with LC- CPFE exhib-
ited poorer OS, compared to patients with LC- PF (although 
this difference was not statistically significant), despite 
both groups exhibiting similar DFS. These findings indicate 
that both groups have a similar risk of recurrence, although 
different prognoses in terms of OS. We presume that this 
difference may be related to a reduced respiratory capacity 
in the lungs of patients with CPFE (because of emphysema 
that is caused by smoking), compared to the respiratory 
capacity of patients with IPF. Moreover, our multivariate 
analyses revealed that CPFE was an independent prognostic 
factor for OS. Therefore, we believe that CPFE should 
be differentiated from IPF among patients who have 
undergone lung resection for lung cancer.
Nineteen of the 72 LC- CPFE cases exhibited adenocar-
cinoma histology, with solid adenocarcinoma (n = 7, 36.8%) 
as the most frequent subclass, no cases of adenocarcinoma 
in situ or minimally invasive adenocarcinoma, and only 
one case of lepidic adenocarcinoma. Moreover, tumors 
without a lepidic component were observed in a majority 
of the cases (n = 12, 63.1%). These findings may indicate 
that lung adenocarcinomas in the CPFE group were dif-
ferent from those in the non- CPFE group. After the IASLC/
ATS/ERS multidisciplinary classifications of lung adenocar-
cinoma were published in 2011 [20], many studies have 
reported the frequency of lung adenocarcinoma subclasses, 
with the most common being papillary predominant adeno-
carcinoma or acinar predominant adenocarcinoma [21–25]. 
Moreover, no studies have reported solid adenocarcinoma 
as the most common histological subclass of lung adeno-
carcinoma. Although we did not histologically compare the 
lung adenocarcinoma subclasses between patients with and 
without CPFE in this cohort, we speculate that lung adeno-
carcinoma in patients with CPFE is a unique lung cancer, 
which can develop from the dysplastic epithelium in the 
fibrotic area via a process that is similar to that for squa-
mous cell carcinoma. Furthermore, we observed that most 
adenocarcinomas in the CPFE group grew along the irregular 
fibrous wall and intermingled with non- neoplastic glands 
in the fibrotic area. In these cases, it is very hard to deter-
mine the lung adenocarcinoma subclass, and we question 
whether these should be considered as the lepidic or acinar 
pattern. Given all these findings, we suggest that lung 
adenocarcinoma in patients with CPFE should be considered 
as a particular subclass (e.g., “invasive adenocarcinoma with 
fibrosis”). However, further studies with a larger sample 
size are needed to validate these findings.
In conclusion, the findings of this study indicate that 
LC- CPFE may arise from dysplastic epithelium in the 
fibrotic area around the tumor, and that the process of 
developing lung cancer may be similar to that of LC- PF. 
However, as our patients with LC- CPFE exhibited sig-
nificantly poorer outcomes, we suggest that CPFE should 
be considered as an important background disease for 
patients who have undergone resection for lung cancer.
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